Applications in Nuclear Medicine – Diagnostics

Session Organizers:
Cathy Cutler, University of Missouri, USA
Buck Rogers, Washington University–St. Louis, USA

Diagnostics are radiopharmaceuticals that consist of radionuclides for the non-invasive imaging of disease or function. The radionuclide is either attached to a targeting vector that determines it’s localization and thus act as a radiotracer or to a ligand that’s overall properties such as charge and hydrophobicity determine its localization. This session will cover recent developments in the synthesis and evaluation of novel radioactive ligands that can be used for the detection and diagnosis of a variety of diseases. Topic areas will include new small molecules, antibodies, antibody fragments, peptides, and nanoparticles in the preclinical and potentially the clinical setting.


44mSc/44Sc in vivo generator: radiolabeling and biological evaluation for radiopharmaceutical development
Sandrine Huclier-Markai, Laboratoire SUBATECH, GIP Cyclotron Arronax, France

New SPECT Tracers in the Era of PET: Nice to have or need to have?
Roger Schibli, Center for Radiopharmaceutical Sciences, Paul Scherrer Institut, Switzerland

The Site-Specific Radiolabeling of Antibodies on the Heavy Chain Glycans
Brian Zeglis, Department of Radiology, Memorial Sloan-Kettering Cancer Center, United States

Diagnostic Imaging with 68Ga-Biophosphonates
Frank Rösch,J ohannes Gutenberg Universität Mainz, Institut für Kernchemie, Germany

Radiometal-Based ImmunoPET Imaging of Cancer
Hao Hong, Department of Radiology, University of Wisconsin – Madison, United States

Development of metrology tools for enhancing the quantitative value of Positron Emission Tomography
Brian Zimmerman, NIST, Radiation Physics Division, United States

Nucleophilic F-18 Fluorination for Bioconjugation Chemistry: Its Applications to Imaging Agents
Dae Yoon Chi, Sogang University, Korea